Tumor agnostic therapy represents a newer approach in cancer treatment, shifting the focus from the cancer’s origin location to its specific molecular characteristics. This innovative strategy targets certain genetic changes or molecular alterations found within the cancer cells, regardless of where the tumor first appeared in the body. It recognizes that cancers from different organs can share similar underlying molecular drivers, making them susceptible to the same targeted treatments. This method aims to provide a more precise way to combat cancer by addressing the common features that drive its growth.
Understanding Tumor Agnostic Therapy
Traditional cancer treatments often categorize and treat cancers based on the organ or tissue where they originated, such as lung cancer or breast cancer. This approach largely tailors treatments to the specific organ-defined cancer. Tumor agnostic therapy moves beyond this organ-centric view, focusing on shared molecular features. For example, a genetic mutation driving cancer growth in the colon might also be present in a lung tumor.
The fundamental principle is that certain molecular alterations, like gene fusions or DNA repair deficiencies, can be found across various cancer types. Instead of treating “lung cancer,” this approach treats a cancer with a specific genetic signature, regardless of its starting point. This allows for a uniform treatment strategy for diverse cancers that share the same molecular vulnerability. This paradigm shift enables a more personalized and precise treatment based on the cancer’s unique biological makeup rather than its anatomical location.
Key Biomarkers and Targeted Cancers
Specific genetic mutations or molecular alterations, known as biomarkers, are central to tumor agnostic therapy. One such biomarker is a neurotrophic receptor tyrosine kinase (NTRK) gene fusion, which occurs when parts of the NTRK gene join with other genes. This fusion leads to abnormal TRK fusion proteins that drive uncontrolled cell growth across many different cancer types. Therapies designed to inhibit these TRK fusion proteins have shown effectiveness in various cancers, including soft tissue sarcomas, thyroid cancers, and lung cancers.
Another significant biomarker is high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR). Microsatellites are repetitive DNA sequences, and MSI-H indicates a high number of errors in these sequences due to a faulty DNA repair system. This deficiency, dMMR, can arise in a variety of tumors, making cells more susceptible to certain immunotherapies. Cancers frequently exhibiting MSI-H/dMMR include colorectal cancer, endometrial cancer, and some gastric cancers. The presence of these biomarkers, regardless of cancer origin, guides the selection of targeted treatments.
Identifying Eligible Patients
Identifying patients who can benefit from tumor agnostic therapy relies on advanced diagnostic techniques. Comprehensive genomic profiling (CGP) or molecular testing of tumor tissue is a necessary step. This testing involves analyzing the tumor’s DNA and RNA to detect specific genetic mutations, gene fusions, or other molecular alterations. Techniques such as next-generation sequencing (NGS) are commonly employed to scan for these biomarkers.
These sophisticated tests identify the unique molecular blueprint of an individual’s cancer, revealing actionable biomarkers. The results of this testing guide oncologists in determining if a patient’s cancer possesses the specific molecular characteristic that a tumor agnostic therapy is designed to target. Without this detailed molecular information, it would not be possible to match the patient with the appropriate biomarker-driven treatment.
Advantages of the Tumor Agnostic Approach
The tumor agnostic approach offers several advantages for patients. This strategy provides a highly targeted treatment that directly addresses the specific molecular drivers of a patient’s cancer. Because these therapies are designed to interfere with precise cancer-promoting pathways, they can potentially lead to fewer side effects compared to traditional chemotherapy, which often affects healthy cells alongside cancer cells. This precision can improve the patient’s quality of life during treatment.
This approach also expands treatment options, especially for patients with rare mutations or advanced cancers that have not responded to conventional therapies. It opens new avenues for individuals whose cancers might otherwise have limited treatment choices. By focusing on the underlying molecular pathology rather than the tumor’s location, tumor agnostic therapy can offer effective solutions for a broader range of cancer presentations.
Navigating Tumor Agnostic Treatment
Patients considering tumor agnostic treatment should engage in thorough discussions with their oncology team. These conversations are important for understanding all available treatment options and determining if this approach aligns with their specific cancer profile. The availability of comprehensive genomic profiling and specific tumor agnostic therapies can vary depending on healthcare systems and regional access to specialized centers.
While promising, these therapies are not universally applicable to all cancer patients. They are contingent upon the identification of specific biomarkers within the tumor. Patients need to understand that the success of this treatment relies entirely on the presence of these particular molecular alterations, which are detected through specialized testing.
References
Drilon, A., Laetsch, T. W., Kummar, A., DuBois, S. G., Mascarenhas, L., Turpin, B., … & Hyman, D. M. (2018). Efficacy and safety of larotrectinib in patients with TRK fusion–positive cancers: a multicentre, open-label, phase 1–2 study. The Lancet Oncology, 19(12), 1632-1640.
Le, D. T., Durham, J. N., Smith, K. N., Wang, Y., Bartlett, B. R., Aulakh, L. K., … & Diaz Jr, L. A. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357(6352), 409-413.
MacConaill, L. E., & Van Allen, E. M. (2018). Clinical genomics: comprehensive genomic profiling for cancer. Cold Spring Harbor Perspectives in Medicine, 8(8), a029672.